XML 54 R28.htm IDEA: XBRL DOCUMENT v3.19.2
EARNINGS (LOSS) PER SHARE ATTRIBUTABLE TO THE STOCKHOLDERS OF ARGAN, INC. (Tables)
6 Months Ended
Jul. 31, 2019
EARNINGS (LOSS) PER SHARE ATTRIBUTABLE TO THE STOCKHOLDERS OF ARGAN, INC.  
Schedule of computations of basic and diluted earnings (loss) per share

 

Basic and diluted earnings (loss) per share are computed as follows (shares in thousands except in the footnote below the charts):

 

 

 

 

 

 

 

 

 

 

Three Months Ended July 31, 

 

    

2019

    

2018

 

 

 

 

 

 

 

Net income attributable to the stockholders of Argan, Inc.

 

$

1,154

 

$

16,972

 

 

 

 

 

 

 

Weighted average number of shares outstanding - basic

 

 

15,633

 

 

15,568

Effects of stock awards (1)

 

 

124

 

 

105

Weighted average number of shares outstanding - diluted

 

 

15,757

 

 

15,673

Net income per share attributable to the stockholders of Argan, Inc.

 

 

 

 

 

 

Basic

 

$

0.07

 

$

1.09

Diluted

 

$

0.07

 

$

1.08

 

 

 

 

 

 

 

 

 

 

Six Months Ended July 31, 

 

    

2019

    

2018

 

 

 

 

 

 

 

Net (loss) income attributable to the stockholders of Argan, Inc.

 

$

(28,646)

 

$

21,809

 

 

 

 

 

 

 

Weighted average number of shares outstanding - basic

 

 

15,608

 

 

15,568

Effects of stock awards (1)

 

 

 —

 

 

105

Weighted average number of shares outstanding - diluted

 

 

15,608

 

 

15,673

Net (loss) income per share attributable to the stockholders of Argan, Inc.

 

 

 

 

 

 

Basic

 

$

(1.84)

 

$

1.40

Diluted

 

$

(1.84)

 

$

1.39


(1)

For the three months ended July 31, 2019, the weighted average number of shares determined on a dilutive basis excludes the effect of antidilutive stock options covering 530,000 shares of common stock. For the six months ended July 31, 2019, all common stock equivalents are considered to be antidilutive as the Company incurred a net loss for the period. The numbers for the three and six months ended July 31, 2018 exclude the effects of antidilutive stock options covering 486,500 shares, which had exercise prices per share in excess of the average market price per share for the applicable period.